Cargando…

Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis

The new SARS-CoV-2 coronavirus is the causative agent of the COVID-19 pandemic outbreak that affected more than 190 countries worldwide with more than 292,000 confirmed cases and over 12,700 deaths. There is at the moment no vaccine or effective treatment for this disease which constitutes a serious...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hakmi, Mohammed, Bouricha, El Mehdi, Kandoussi, Ilham, Harti, Jaouad El, Ibrahimi, Azeddine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Biomedical Informatics 2020
Materias:	Research-Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392094/ https://www.ncbi.nlm.nih.gov/pubmed/32773989 http://dx.doi.org/10.6026/97320630016301

Ejemplares similares

Facing Antitubercular Resistance: Identification of Potential Direct Inhibitors Targeting InhA Enzyme and Generation of 3D-pharmacophore Model by in silico Approach
por: EL Haddoumi, Ghyzlane, et al.
Publicado: (2023)

In Silico Identification of Natural Food Compounds as Potential Quorum-Sensing Inhibitors Targeting the LasR Receptor of Pseudomonas aeruginosa
por: Magri, Meryam, et al.
Publicado: (2023)

Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approach
por: Akachar, Jihane, et al.
Publicado: (2020)

In silico analysis of ACE2 orthologues to predict animal host range with high susceptibility to SARS-CoV-2
por: Bouricha, El Mehdi, et al.
Publicado: (2020)

Docking analysis of verteporfin with YAP WW domain
por: Kandoussi, Ilham, et al.
Publicado: (2017)

Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers
por: Kandoussi, Ilham, et al.
Publicado: (2020)

In Silico Analyses of All STAT3 Missense Variants Leading to Explore Divergent AD-HIES Clinical Phenotypes
por: Mansouri, Mariam, et al.
Publicado: (2023)

Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules
por: Allam, Loubna, et al.
Publicado: (2020)

Selective Non-toxics Inhibitors Targeting DHFR for Tuberculosis and Cancer Therapy: Pharmacophore Generation and Molecular Dynamics Simulation
por: Haddoumi, Ghyzlane EL, et al.
Publicado: (2023)

Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
por: Arrouchi, Housna, et al.
Publicado: (2019)

Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study
por: Refaey, Rana H., et al.
Publicado: (2021)

AKT1 Polymorphism (rs10138227) and Risk of Colorectal Cancer in Moroccan Population: A Case Control Study
por: Allam, Loubna, et al.
Publicado: (2020)

Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach
por: Hasan, Mahmudul, et al.
Publicado: (2021)

A molecular docking study of potential inhibitors and repurposed drugs against SARS-CoV-2 main protease enzyme()
por: Ercan, Selami, et al.
Publicado: (2021)

Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (M(Pro))
por: EL Khatabi, Khalil, et al.
Publicado: (2022)

Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations
por: Omer, Samia E., et al.
Publicado: (2022)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022)

In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
por: Kumar, Yogesh, et al.
Publicado: (2020)

Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs
por: Bhardwaj, Vijay Kumar, et al.
Publicado: (2021)

Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
por: Jain, Rashi, et al.
Publicado: (2020)

Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
por: Ghahremanpour, Mohammad M., et al.
Publicado: (2020)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Targeted Gene Panel Sequencing Unveiled New Pathogenic Mutations in Patients With Breast Cancer
por: Kartti, Souad, et al.
Publicado: (2023)

Repurposing of known drugs for COVID-19 using molecular docking and simulation analysis
por: Bhanu1, Piyush, et al.
Publicado: (2023)

Design of Potent Inhibitors Targeting the Main Protease of SARS-CoV-2 Using QSAR Modeling, Molecular Docking, and Molecular Dynamics Simulations
por: Oubahmane, Mehdi, et al.
Publicado: (2023)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
por: BATIBAY, Gönül S., et al.
Publicado: (2023)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor
por: Hu, Xiaopeng, et al.
Publicado: (2020)

Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors
por: Cardoso, Wesley B., et al.
Publicado: (2021)

Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease
por: Marinho, Emanuelle Machado, et al.
Publicado: (2020)

IDbSV: An Open-Access Repository for Monitoring SARS-CoV-2 Variations and Evolution
por: Essabbar, Abdelmounim, et al.
Publicado: (2021)

Molecular docking and dynamics simulation of main protease of SARS-CoV-2 with naproxen derivative
por: K Hussein, Rageh, et al.
Publicado: (2023)

Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease
por: Hussien, Mostafa A., et al.
Publicado: (2020)

Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease
por: Owis, Asmaa I., et al.
Publicado: (2020)

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method
por: Sencanski, Milan, et al.
Publicado: (2020)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
por: Jo, Seri, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f4hta34jjg9l9iadf157m6a4sr